Nothing Special   »   [go: up one dir, main page]

IS6759A - Ný þíadíasól og oxadíasól og notkun þeirra sem fosfórdíesterasa-7 hindra - Google Patents

Ný þíadíasól og oxadíasól og notkun þeirra sem fosfórdíesterasa-7 hindra

Info

Publication number
IS6759A
IS6759A IS6759A IS6759A IS6759A IS 6759 A IS6759 A IS 6759A IS 6759 A IS6759 A IS 6759A IS 6759 A IS6759 A IS 6759A IS 6759 A IS6759 A IS 6759A
Authority
IS
Iceland
Prior art keywords
phosphodiesterase
oxadiazole
inhibitors
thiadiazole
new
Prior art date
Application number
IS6759A
Other languages
English (en)
Inventor
Vergne Fabrice
Ducrot Pierre
Andrianjara Charles
Bernardelli Patrick
Lorthiois Edwige
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of IS6759A publication Critical patent/IS6759A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IS6759A 2000-10-02 2003-03-27 Ný þíadíasól og oxadíasól og notkun þeirra sem fosfórdíesterasa-7 hindra IS6759A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402710A EP1193261A1 (en) 2000-10-02 2000-10-02 New thiadiazoles and their use as phosphodiesterase-7 inhibitors
PCT/EP2001/011330 WO2002028847A1 (en) 2000-10-02 2001-10-01 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors

Publications (1)

Publication Number Publication Date
IS6759A true IS6759A (is) 2003-03-27

Family

ID=8173891

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6759A IS6759A (is) 2000-10-02 2003-03-27 Ný þíadíasól og oxadíasól og notkun þeirra sem fosfórdíesterasa-7 hindra

Country Status (43)

Country Link
US (1) US7122565B2 (is)
EP (2) EP1193261A1 (is)
JP (1) JP4177098B2 (is)
KR (1) KR100614158B1 (is)
CN (1) CN1639141A (is)
AP (1) AP1541A (is)
AR (1) AR035347A1 (is)
AT (1) ATE304003T1 (is)
AU (2) AU8994501A (is)
BG (1) BG107654A (is)
BR (1) BR0114391A (is)
CA (1) CA2424279A1 (is)
CZ (1) CZ2003857A3 (is)
DE (1) DE60113283T2 (is)
DK (1) DK1326853T3 (is)
DZ (1) DZ3440A1 (is)
EA (1) EA007179B1 (is)
EC (1) ECSP034534A (is)
EE (1) EE200300134A (is)
ES (1) ES2247166T3 (is)
GE (1) GEP20053459B (is)
GT (1) GT200100196A (is)
HN (1) HN2001000217A (is)
HR (1) HRP20030247A2 (is)
HU (1) HUP0301248A3 (is)
IL (1) IL155122A0 (is)
IS (1) IS6759A (is)
MA (1) MA25916A1 (is)
MX (1) MXPA03002839A (is)
NO (1) NO20031482D0 (is)
NZ (1) NZ524852A (is)
OA (1) OA12518A (is)
PA (1) PA8529501A1 (is)
PE (1) PE20020419A1 (is)
PL (1) PL366332A1 (is)
PT (1) PT1326853E (is)
SI (1) SI1326853T1 (is)
SK (1) SK3812003A3 (is)
SV (1) SV2003000633A (is)
TN (1) TNSN01139A1 (is)
WO (1) WO2002028847A1 (is)
YU (1) YU24503A (is)
ZA (1) ZA200302346B (is)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1597385A1 (en) * 2002-11-13 2005-11-23 Bayer HealthCare AG DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1)
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
EP1775298B1 (en) 2004-07-01 2013-03-20 Daiichi Sankyo Company, Limited Thienopyrazole derivative having pde7 inhibitory activity
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CN104758291B (zh) * 2007-03-27 2020-03-03 奥默罗斯公司 用于治疗运动障碍的pde7抑制剂的用途
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
NZ610925A (en) 2010-11-08 2015-10-30 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN102276625B (zh) * 2011-08-24 2013-07-17 天津药物研究院 噻二唑衍生物
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103288777A (zh) * 2013-05-28 2013-09-11 浙江禾田化工有限公司 特丁噻草隆关键中间体2-甲基氨基-5-叔丁基-1,3,4-噻二唑的合成方法
US9416652B2 (en) 2013-08-08 2016-08-16 Vetco Gray Inc. Sensing magnetized portions of a wellhead system to monitor fatigue loading
SG10201911989SA (en) * 2015-06-12 2020-02-27 Oryzon Genomics Sa Biomarkers associated with lsd1 inhibitors and uses thereof
CN107674042B (zh) * 2017-09-28 2020-09-25 河南科技大学 一种超声波无溶剂合成噻二唑类化合物的方法
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251979C (is)
FR2388806A1 (fr) 1977-04-25 1978-11-24 Gulf Oil Corp Nouvelles 3-benzyl-2-methylimino-5-phenyl4-1,3,4 thiadiazolines et leur application au desherbage chimique de cultures
DK270880A (da) * 1979-07-09 1981-01-10 Gulf Oil Corp Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler
DD247003A1 (de) * 1985-11-07 1987-06-24 Hydrierwerk Rodleben Veb Verfahren zur herstellung von in 2-stellung mit amninhaltigen gruppen subst. 7 h-1,3,4-thiadiazolo(3,2-a)pyrimidinen
DD251979A1 (de) * 1986-08-01 1987-12-02 Neubauer T Paedagog Hochschule Verfahren zur herstellung von s-triazinylsubstituierten 2-imino-1,3,4-oxadiazolinen
DE4418066A1 (de) 1994-05-24 1995-11-30 Bayer Ag Substituierte Thiadiazoline
DE69909592D1 (de) * 1998-02-17 2003-08-21 Roche Diagnostics Gmbh Verwendung von thiadiazolo[4,3-a]pyridine derivaten

Also Published As

Publication number Publication date
ZA200302346B (en) 2004-08-04
PA8529501A1 (es) 2003-06-30
SK3812003A3 (en) 2004-05-04
AP1541A (en) 2006-01-11
AR035347A1 (es) 2004-05-12
US20030045557A1 (en) 2003-03-06
AU2001289945B2 (en) 2005-12-22
KR100614158B1 (ko) 2006-08-21
GEP20053459B (en) 2005-02-25
AU8994501A (en) 2002-04-15
EA200300333A1 (ru) 2003-10-30
EP1326853B1 (en) 2005-09-07
HRP20030247A2 (en) 2005-04-30
NO20031482L (no) 2003-04-01
DE60113283D1 (de) 2005-10-13
US7122565B2 (en) 2006-10-17
SI1326853T1 (sl) 2005-12-31
DK1326853T3 (da) 2005-12-12
YU24503A (sh) 2006-03-03
PT1326853E (pt) 2005-11-30
SV2003000633A (es) 2003-04-03
TNSN01139A1 (en) 2005-11-10
DZ3440A1 (fr) 2002-04-11
HUP0301248A3 (en) 2005-06-28
JP2004510769A (ja) 2004-04-08
MXPA03002839A (es) 2004-09-10
DE60113283T2 (de) 2006-06-08
EE200300134A (et) 2003-08-15
BR0114391A (pt) 2003-06-24
HUP0301248A2 (hu) 2003-10-28
ES2247166T3 (es) 2006-03-01
IL155122A0 (en) 2003-10-31
NZ524852A (en) 2004-09-24
NO20031482D0 (no) 2003-04-01
AP2003002764A0 (en) 2003-03-31
PL366332A1 (en) 2005-01-24
EA007179B1 (ru) 2006-08-25
WO2002028847A1 (en) 2002-04-11
EP1193261A1 (en) 2002-04-03
MA25916A1 (fr) 2003-10-01
EP1326853A1 (en) 2003-07-16
ATE304003T1 (de) 2005-09-15
BG107654A (bg) 2003-12-31
KR20030068542A (ko) 2003-08-21
CZ2003857A3 (cs) 2004-02-18
HN2001000217A (es) 2002-06-13
GT200100196A (es) 2002-07-18
ECSP034534A (es) 2003-07-25
PE20020419A1 (es) 2002-07-18
OA12518A (en) 2006-05-29
JP4177098B2 (ja) 2008-11-05
CN1639141A (zh) 2005-07-13
CA2424279A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
IS6759A (is) Ný þíadíasól og oxadíasól og notkun þeirra sem fosfórdíesterasa-7 hindra
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
GB0025782D0 (en) Use of inhibitors
NO20020343L (no) Kaspase-inhibitorer og anvendelse derav
IS5976A (is) Bensóheteróhringir og notkun theirra sem MEK-hemlar
HK1057214A1 (en) New mandelic acid derivatives and their use as throbin inhibitors
NO20042229L (no) Type 4-fosfodiestemseinhibitorer og anvendelse derav
DK1202941T3 (da) Gipssammensætninger og beslægtede fremgangsmåder
HUP0300061A3 (en) Use of il-18 inhibitors
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
AU5693101A (en) New thiochromane derivatives and their use as thrombin inhibitors
NO20035399L (no) Pyrrolidinoksadiazol- og tiadiazolderivater
HRP20020970A2 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
PT1272456E (pt) Inibidores de angiogenese de hidrazida e alcoxiamida
ZA200205471B (en) Use of IL-18 inhibitors.
AU2002223649A1 (en) Vegh inhibitors and their use
SE0004239D0 (sv) New use of an inhibitor
GB0029733D0 (en) Inhibitors
GB0029730D0 (en) Inhibitors
GB0021193D0 (en) Inhibitors
GB0015996D0 (en) Inhibitors
SE0004405D0 (sv) New composition and use